Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization
| Group | Value (z-scores of activation in cortex) | Spread |
|---|---|---|
| Liraglutide | -0.42 | 0.27 |
| Placebo | 0.53 | 0.37 |
Trial · Interventional
CompletedPhase 4Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI
NCT01562678Mar 2012 to May 2014
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The main purpose of this study is to help us understand the effects of diabetes medication Liraglutide on weight loss and hunger. The investigators have already determined what the highest tolerated dose of Liraglutide is through earlier human research studies. Liraglutide was approved by the FDA in January 2010 for treatment of diabetes. The investigators will also study the following: 1. The impact of Liraglutide on brain responses to food 2. It's effect on physiological and mental performance 3. If its effect on the brain differs among obese and lean diabetic subjects.
Experimental
Liraglutide
Placebo comparator
Placebo
Outcomes the sponsor listed as primary.
Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization
Time frame · 18 days of Liraglutide or placebo treatment
Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (z-scores of activation in cortex) | Spread |
|---|---|---|
| Liraglutide | -0.42 | 0.27 |
| Placebo | 0.53 | 0.37 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Liraglutide14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo and 14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide | – | 0 / 28 | 7 / 28 |
| Placebo14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide and 14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo | – | 0 / 28 | 7 / 28 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
2 studies on this page
Indexing hint: Randomized controlled trial · 2023
Angelidi et al. 2023Metabolism: clinical and experimentalcited by 47
PMID 36375643DOI 10.1016/j.metabol.2022.155346PUB-36375643
Indexing hint: Randomized controlled trial · 2016
Farr et al. 2016Diabetologiacited by 231
PMID 26831302PMC4826792DOI 10.1007/s00125-016-3874-yPUB-26831302
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated